Contact Information:
Daniel is originally from Newport News, Virginia. He received his Doctor of Pharmacy degree from Virginia Commonwealth University in 2025. His practice interests include oncology and cardiology. In addition to his clinical responsibilities, Dr. Deanhofer serves on the Oncology Formulary Evaluation Team and is completing the Teaching and Learning Certificate Program. His research will assess real-world efficacy and safety of capivasertib in hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer. Upon completion of PGY1 pharmacy residency, he plans to pursue a PGY2 in one of his interest areas. In the future, he hopes to obtain board certification, lead and contribute to research, and develop pharmacy-led programs within a large academic medical center. Outside of pharmacy, he enjoys watching and playing sports, listening to music, and collecting sneakers!